Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins45 enrolled

Overview

This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).

MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is believed that using MultiHance may be able to help doctors tell normal liver cells apart from active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve the way patients with hepatocellular carcinoma are managed clinically. We hypothesize that the Multi-Hance contrast material will provide better image definition of treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast agents.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Hepatocellular Carcinoma

Interventions

gadobenate dimeglumine (MultiHance)DRUG

The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE. * International Normalized Ratio (INR) \<1.4 * Platelet count \> 80,000 Exclusion Criteria: * Contraindications to TACE procedure * Unable to have an MRI Scan * Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol * Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias * Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders * Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate\<15cc/min) * Pregnancy

Locations (1)

The Johns Hopkins Hospital

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Nodule Size

Maximal nodule size measured in centimeters

Time frame: 3 months

Nodule Enhancement

Percent area of nodule with enhancement

Time frame: 3 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.